Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
Alzheimer's disease
Amyloid
Clinical meaningfulness
Clinical trials methodology
Outcome research
Preclinical
Secondary prevention
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
25
11
2019
medline:
27
11
2020
entrez:
25
11
2019
Statut:
ppublish
Résumé
Demonstrating the "clinical meaningfulness" of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid-β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression. Cox regression analyses were used to determine whether 3-year slopes on the preclinical Alzheimer's cognitive composite predicted MCI diagnosis and global Clinical Dementia Rating>0 in 267 Aβ+ CN individuals participating in the Harvard Aging Brain Study, Australian Imaging, Biomarker and Lifestyle Study, and Alzheimer's Disease Neuroimaging Initiative. Steeper preclinical Alzheimer's cognitive composite decline over 3 years was associated with increased risk for MCI diagnosis and global Clinical Dementia Rating>0 in the following years across all cohorts. Hazard ratios using meta-analytic estimates were 5.47 (95% CI: 3.25-9.18) for MCI diagnosis and 4.49 (95% CI: 2.84-7.09) for Clinical Dementia Rating>0 in those with subtle decline (>-.14 to -.26 preclinical Alzheimer's cognitive composite standard deviations/year) on longitudinal cognitive testing. Early "subtle cognitive decline" among Aβ+ CN on a sensitive cognitive composite demonstrably increases risk for imminent clinical disease progression and functional impairment.
Identifiants
pubmed: 31759879
pii: S1552-5260(19)35446-9
doi: 10.1016/j.jalz.2019.09.074
pmc: PMC7067681
mid: NIHMS1543705
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-560Subventions
Organisme : AbbVie
Pays : International
Organisme : Eisai Inc.
Pays : International
Organisme : Alzheimer's Association
Pays : United States
Organisme : DOD
ID : W81XWH-12-2-0012
Pays : International
Organisme : Alzheimer's Drug Discovery Foundation
Pays : International
Organisme : CIHR
Pays : Canada
Organisme : Science and Industry Endowment Fund
Pays : International
Organisme : Australian Commonwealth Scientific Industrial and research Organization
Pays : International
Organisme : Alzheimer's Disease Neuroimaging Initiative
Pays : International
Organisme : Hollywood Private Hospital
Pays : International
Organisme : Alzheimer's Australia
Pays : International
Organisme : Biogen
Pays : International
Organisme : NIA NIH HHS
ID : K24 AG035007
Pays : United States
Organisme : Edith Cowan University
Pays : International
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG036694
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG053422
Pays : United States
Organisme : Bristol-Myers Squibb Company
Pays : International
Organisme : Mental Health Research Institute
Pays : International
Organisme : F. Hoffmann-La Roche Ltd.
Pays : International
Organisme : NIBIB NIH HHS
Pays : United States
Organisme : National Health and Medical Research Council
Pays : International
Organisme : NIA NIH HHS
ID : K01 AG051718
Pays : United States
Organisme : BioClinica, Inc.
Pays : International
Organisme : Eli Lilly and Company
Pays : International
Organisme : NIA NIH HHS
ID : 1K23AG053422-01
Pays : United States
Informations de copyright
© 2019 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
Références
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Dement (Amst). 2017 Nov 23;10:121-129
pubmed: 29780861
Arch Neurol. 2009 Dec;66(12):1469-75
pubmed: 20008650
Neurology. 2018 Jul 24;91(4):e300-e312
pubmed: 29959257
Lancet Neurol. 2013 Oct;12(10):957-65
pubmed: 24012374
J Prev Alzheimers Dis. 2016;3(3):138-144
pubmed: 29205252
Ann Neurol. 2011 Jan;69(1):181-92
pubmed: 21280088
Alzheimers Dement. 2010 May;6(3):239-46
pubmed: 20451872
J Nucl Med. 2013 Jan;54(1):70-7
pubmed: 23166389
Alzheimers Dement. 2018 Sep;14(9):1193-1203
pubmed: 29803541
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Ann Neurol. 2012 Oct;72(4):578-86
pubmed: 23109153
Sci Transl Med. 2014 Mar 19;6(228):228fs13
pubmed: 24648338
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
JAMA Neurol. 2014 Nov;71(11):1379-85
pubmed: 25222039
JAMA Neurol. 2014 Aug;71(8):961-70
pubmed: 24886908
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
J Am Geriatr Soc. 2018 Apr;66(4):671-678
pubmed: 29341070
Neurology. 2014 May 20;82(20):1760-7
pubmed: 24748674
Int J Geriatr Psychiatry. 2019 Nov;34(11):1623-1632
pubmed: 31318090
Am J Geriatr Psychiatry. 2020 Jan;28(1):64-71
pubmed: 31186157
Neuroimage. 2017 Jan;144(Pt B):255-258
pubmed: 25843019
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Brain. 2014 Jan;137(Pt 1):221-31
pubmed: 24176981
Alzheimers Res Ther. 2019 Jul 8;11(1):61
pubmed: 31286994
Neuropsychologia. 2012 Oct;50(12):2880-2886
pubmed: 22940426
J Prev Alzheimers Dis. 2019;6(2):85-89
pubmed: 30756114
Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677
pubmed: 29264389
J Alzheimers Dis. 2018;65(4):1313-1325
pubmed: 30149452